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Abstract
Antiepileptic drugs (AED) have been associated to in vivo deleterious consequences in bone tissue. The present work aimed 
to characterize the cellular and molecular effects of five different AED on human osteoclastogenesis and osteblastogenesis. 
It was observed that the different drugs had the ability to differentially modulate both processes, in a way dependent on the 
identity and dose of the AED. Shortly, valproic acid stimulated either osteoclastogenesis and osteoblastogenesis, whereas 
carbamazepine, gabapentin, and lamotrigine revealed an opposite behavior; topiramate elicited a decrease of 
osteoclast development and an increase in osteoblast differentiation. This is the first report describing the direct effects 
of different AED on human primary bone cells, which is a very important issue, because these drugs are usually consumed in 
long‐term therapeutics, with acknowledged in vivo effects in bone tissue.
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1 | INTRODUCTION
Epilepsy is a common neurological disorder, affecting about 50 million
people (Fan et al., 2016). Antiepileptic drugs (AED) are a widely used
class of drugs, indicated for the treatment of epilepsy, convulsions,
seizures, pain, neuropathy, and psychiatric disorders (Fan et al., 2016;
Hant & Bolster, 2016; Pitetzis, Spilioti, Yovos, & Yavropoulou, 2017).
Their intake is associated with a variety of side effects, including
dizziness, drowsiness, mental slowing, skin rashes, hepatotoxicity,
pancreatic insufficiency, behavioral disorders, increased risk of meta-
bolic syndrome, and nephrolithiasis (Fan et al., 2016; Lin et al., 2016). In
addition, since the late 60s there is growing evidence pointing to a
disruption of bone metabolism and a decreased bone mineral density,
particularly in children and adolescents (Hant & Bolster, 2016; Lin et al.,
2016; Pitetzis et al., 2017; Rauchenzauner et al., 2010), supported by an
increased risk of fracture, rickets, osteomalacia, osteoporosis, abnormal
dentition, and decreased growth (Carbone et al., 2010; Lazzari et al.,
2013; Shen, Chen, Zhang, Guo, & Ding, 2014). In line with this, it was
reported that valproic acid and lamotrigine and, especially, a combina-
tion of both, is associated with a decreased stature (Guo, Ronen, &
Atkinson, 2001), though the underlying mechanisms are not yet
understood. The real effects of AED in bone tissue remain to be
elucidated and are involved in some controversy, since some studies
have failed to prove a consistent relationship, for example, between
valproic acid and carbamazepine in bone development and growth
(Rattya, Vainionpaa, Knip, Lanning, & Isojarvi, 1999). AED mechanisms
of action with a potential impact in bone tissue are diverse, including
modulation of cytochrome P450 activity, inhibition of osteocalcin
production/function, stimulation of vitamin D catabolism, and increased
calcium excretion in the urine (Ecevit, Aydogan, Kavakli, & Altinoz,
2004; Pitetzis et al., 2017). Globally, although there are many in vivo
observations that point to a possible dysregulation of bone metabolism
by AED, at the present, the data regarding the direct effects of those
drugs on bone cells are still very scarce (Hatakeyama et al., 2011;
Humphrey, Morris, & Fuller, 2013; Schroeder & Westendorf, 2005;
Schroeder, Nair, Staggs, Lamblin, & Westendorf, 2007).
Bone is a very dynamic tissue that is constantly being shaped,
molded, and remodeled by the coordinated action of two major cell
types, the osteoclasts and the osteoblasts (Siddiqui & Partridge,
2016). The former are specialized cells in bone resorption, which
degrade bone extracellular matrix by two different mechanisms,
namely, the secretion of H+ that leads to acid erosion of bone mineral
content, and the secretion of proteases, which digest extracellular
matrix proteins, mainly collagen type 1 (Soysa & Alles, 2016). On the
other hand, osteoblasts synthesize new bone tissue, by lying down
layers of collagen and other proteins, forming the so‐called osteoid
and, after that, depositing nanocrystals of hydroxyapatite (Valenti,
Dalle Carbonare, & Mottes, 2016). Imbalances between both
activities can lead to abnormalities in bone composition, structure
and, consequently, function.
The aim of the present work was to investigate whether different
AED (valproic acid, carbamazepine, gabapentin, lamotrigine, and
topiramate) have the ability to directly affect human osteoclastogen-
esis and osteoblastogenesis. For that, primary osteoclasts and
osteoblasts were used, and cell cultures were characterized for
different biochemical and molecular parameters, as well as for the
involvement of several intracellular signaling pathways in cell
response, in the presence of the tested AED.
2 | MATERIALS AND METHODS
2.1 | Osteoclastic cell cultures
Human peripheral blood mononuclear cells (PBMC) were used as
osteoclastic precursors. They were isolated from the blood of healthy
donors with 25–35 years old, after the informed consent, as described
previously (Costa‐Rodrigues, Carmo, Perpetuo, Monteiro, & Fernandes,
2016b). Shortly, after dilution with phosphate‐buffered saline (PBS) +
2mM EDTA (1:1), blood was applied on top of Ficoll‐Paque™
PREMIUM (GE Healthcare Bio‐Sciences, Chicago, Illinois, EUA) and
centrifuged at 400 g for 30min. PBMC were collected, washed two
times with PBS + 2mM EDTA and counted with a cytometer (Celltac
MEK‐5103, Nihon Kohden, Tokyo, Japan). Usually, for each 100ml of
processed blood, about 70 × 106 PBMC were obtained.
Cells were seeded at 1.5 × 106 cells/cm2 in Minimum Essential
Medium Eagle‐alpha modification (α‐MEM) supplemented with 30%
autologous human serum, 100 IU/ml penicillin, 2.5 µg/ml streptomycin,
2.5 µg/ml amphotericin B, and 2mM L‐glutamine. Cell cultures were
maintained for 21 days in a 5% CO2 humidified atmosphere at 37°C,
and culture medium was replaced once a week.
Twenty‐four hours after cell seeding, cells were treated with a
wide range of the different tested AED (10−8–10−4M), which
included the plasma levels normally achieved following the ther-
apeutic usage of the drugs (Abou‐Khalil, 2005; Haroutiunian, Ratz,
Rabinovich, Adam, & Hoffman, 2009; O'Dougherty, Wright, Cox, &
Walson, 1987; Popov, Maricic, Prosen, & Voncina, 2013; Rose & Kam,
2002). The tested AED were valproic acid, carbamazepine, gabapen-
tin, lamotrigine, and topiramate. In addition, cell cultures were also
supplemented with the classic osteoclastogenic promoters M‐CSF
(25 ng/ml) and RANKL (40 ng/ml; Costa‐Rodrigues, Martins, &
Fernandes, 2012). Both the AED and the M‐CSF and RANKL were
renewed at each medium change. Cultures were assessed for the
tartrate‐resistant acid phosphatase (TRAP) activity, the presence of
TRAP +multinucleated cells, apoptosis and the presence of actin
rings, vitronectin receptor (VNR), and calcitonin receptor (CTR), at
days 7, 14, and 21.
Cultures treated with the minimum tested concentration of each
AED that elicited a significant effect in osteoclastic behavior (valproic
acid, gabapentin, and lamotrigine: 10−7 M; carbamazepine and
topiramate: 10−6M), were characterized for the expression of
osteoclastic genes, calcium phosphate resorbing ability, and for the
involvement of several intracellular pathways in cell response.
Cultures were assessed at days 7, 14, and 21.
2.2 | Osteoblastic cell cultures
Human mesenchymal stem cells derived from bone marrow (HMSC,
Innoprot, Bizkaia, Spain), were used as osteoblastic precursors. HMSC
were maintained in α‐MEM supplemented with 10% fetal bovine serum
(FBS), 100 IU/ml penicillin, 2.5 µg/ml streptomycin, 2.5 µg/ml amphoter-
icin B, and 50 μg/ml ascorbic acid. After reaching ~70–80% confluence,
cells were detached with 0.05% trypsin + 0.5mM EDTA and seeded at
3.3 × 103 cells/cm2. Cell cultures were performed for 21 days in the
same culture medium, being incubated in a 5% CO2 humidified
atmosphere at 37°C. Culture medium was replaced once a week.
Cell cultures were exposed to a wide range of the different tested
AED (10−8–10−4M), 24 hr after cell seeding, in the presence of the
osteogenic inducer dexamethasone (10 nM; Costa‐Rodrigues, Reis,
Castro, & Fernandes, 2016a). The tested AED were valproic acid,
carbamazepine, gabapentin, lamotrigine, and topiramate. Both the
AED and the dexamethasone were renewed at each medium change.
Cultures were assessed for the alkaline phosphatase (ALP) activity,
cell viability, apoptosis, and cellular morphology at days 7, 14, and 21.
Cultures treated with the minimum tested concentration of each
AED that elicited a significant effect in osteoblastic behavior
(valproic acid, carbamazepine, and lamotrigine: 10−6M; gabapentin
and topiramate: 10−7 M), were further assessed for expression of
osteoblastic genes and for the involvement of several intracellular
pathways in cell response. Cultures were assessed at days 7, 14,
and 21.
2.3 | Characterization of cellular responses
2.3.1 | Tartrate‐resistant acid phosphatase (TRAP)
and alkaline phosphatase (ALP) activities
TRAP and ALP activities were determined by the para‐nitrophenyl-
phosphate (pNPP) hydrolysis assay. For that, after being washed two
times with PBS, cells were solubilized with 0.1% (V/V) Triton X‐100.
For the TRAP activity quantification, cellular extracts were incubated
(1 hr, 37°C) with 12.5 mM pNPP prepared in 0.04M tartaric acid and
0.09M citrate (pH 4.8); for the ALP activity analysis, cellular extracts
were incubated (30min, 37°C) with 12.5 mM pNPP in alkaline buffer
solution, pH 10.3. In both methods, after addition of 5M NaOH, the
absorbance of the samples was measured at 400 nm in an ELISA plate
reader (Synergy HT, Biotek, Winooski, Vermont, EUA). TRAP and
ALP activities were normalized with total protein content quantified
by the Bradford's method (Bradford, 1976), and results are expressed
as nmol/min.μgprotein
−1.
2.3.2 | TRAP‐positive multinucleated cells
PBMC cultures were washed two times with PBS and fixed for 10min
with 3.7% formaldehyde. Following, cells were stained for TRAP with
acid phosphatase, leukocyte (TRAP) kit (Sigma, MO), according to
manufacturer's instructions. For that, cells were incubated with
0.12mg/ml naphtol hAS‐BI, in the presence of 6.76mM tartrate and
0.14mg/ml Fast Garnet GBC, for 1 hr at 37°C, in the dark. After
incubation, cell layers were washed, stained with hematoxylin and
TRAP‐positive multinucleated cells were counted under a phase
contrast microscope (Nikon TMS, Tokyo, Japan).
2.3.3 | Calcium staining
HMSC cultures were washed two times with PBS and fixed with 3.7%
formaldehyde for 10min. After incubation, cell layers were covered
with a 1% alizarin sodium solution (0.028% in NH4OH), pH 6.4, 2 min,
and then rinsed with distilled water and acid ethanol (ethanol, 0.01%
HCL). Calcium deposits stained red.
2.3.4 | Cell viability
Cell viability was assessed by the MTT assay, which is based on the
reduction of the tetrazolium salt MTT (3‐[4,5‐dimethylthiazol‐2‐yl]‐
2,5‐diphenyltetrazolium bromide; 0.5mg/mL), by viable cells to form a
purple formazan product after 3 hr of incubation. After solubilization
in dimethyl sulfoxide (DMSO), the absorbance of the samples was
measured at 545 nm on a microplate reader (Synergy HT, Biotek).
2.3.5 | Apoptosis quantification
Apoptosis was assessed by the caspase‐3 activity quantification. Briefly,
cells were washed two times with PBS and evaluated for the caspase‐3
activity with EnzCheck® Caspase‐3 Assay Kit #2 (Molecular Probes,
Eugene), according to manufacturer's instructions. Fluorescence was
measured at 496/520 nm (excitation/emission) in an ELISA plate reader
(Synergy HT, Biotek). Results obtained in each experimental condition
were normalized with the value obtained in the corresponding control
(absence of AED) and were presented as a % of response compared
with the control.
2.3.6 | Actin, vitronectin receptor (VNR), and
calcitonin receptor (CTR) staining
Cell cultures were washed with PBS and fixed with 3.7% formalde-
hyde, for 10min at room temperature. After that, cells were
permeabilized with 0.1% Triton X‐100, for 5min, and stained for actin
with 5U/ml Alexa Fluor1 647‐Phalloidin (Invitrogen, Carlsbad,
California, EUA), and, in the case of PBMC cultures, also for vitronectin
and calcitonin receptors (VNR and CTR) with 50mg/ml mouse IgGs
anti‐VNR and IgGs anti‐CTR (R&D Systems, Minneapolis, EUA),
respectively. Detection of IgGs anti‐VNR and IgGs anti‐CTR was
conducted with 2mg/ml Alexa Fluor1 488‐Goat antimouse IgGs. Cells
were observed under confocal laser scanning microscopy (CLSM).
2.3.7 | Osteoclast and osteoblast gene expression
Gene expression was evaluated by quantitative real‐time polymerase
chain reaction (qPCR). The tested housekeeping genes were beta‐
glucuronidase (GUSB) and proteasome subunit beta type‐6 (PSMB6).
The analyzed osteoclast‐related genes were c‐myc, c‐src, TRAP,
cathepsin K (CATK), and carbonic anhydrase 2 (CA2; Costa‐Rodrigues
et al., 2014) and the osteoblast‐related genes were collagen type 1
(COL1), ALP, and bone morphogenetic protein 2 (BMP2; Costa‐
Rodrigues et al., 2016a). RNA was isolated with a RNeasy® Mini Kit
(QIAGEN, Hilden, Germany) according to manufacturer's instruc-
tions. Reverse transcription complementary DNA (cDNA) synthesis
was performed with the DyNAmo cDNA synthesis kit (Finnzymes,
Finland) and random hexamers according to the manufacturer's
instructions. Following, cDNA samples (2 ng) were amplified with a
DyNAmo Flash SYBR green qPCR kit (Finnzymes) on a Rotor‐Gene
thermocycler (Qiagen). The annealing temperature was 55°C and the
extension time was 15 s. The primers used are listed in Table 1. The
values obtained were normalized with the results obtained for the
two tested housekeeping genes.
2.3.8 | Calcium phosphate resorbing ability
For resorbing ability assay, PBMC cultures were performed on
calcium phosphate coated culture plates (BD BioCoat™ Osteolo-
gic™ Bone Cell Culture Plates, BD Biosciences, NJ). Cells were
maintained for 21 days in the absence or presence of AED. At the
end of the culture period, cells were bleached with 6% NaOCl and
5.2% NaCl, and the remaining calcium phosphate layers were
visualized under phase contrast light microscopy (Nikon TMS,
Tokyo, Japan). Resorption lacunae were identified and total
resorbed area was quantified with ImageJ 1.41 software. Results
are presented as a % of resorbed area.
2.3.9 | Intracellular signaling mechanisms
The ability of AED to modulate several common signaling pathways
involved either in osteoclastogenesis (Costa‐Rodrigues et al., 2016b;
Soysa & Alles, 2016) and osteoblastogenesis (Costa‐Rodrigues et al.,
2016a; Valenti et al., 2016) was assessed. For that, PBMC and HMSC
cultures were treated with the minimum AED concentration that elicited
a significant response on each cell type, and simultaneously, with
commercial signaling pathway inhibitors (the AED and the inhibitors were
renewed at each medium change). The tested pathways were: MEK
(inhibitor U0126, 1 µM), NFkB (inhibitor PDTC, 10 µM), PKC (inhibitor
GO6983, 5 µM), and JNK (inhibitor SP600125, 10 µM). Cultures were
assessed for TRAP (PBMC cultures) and ALP (HMSC cultures) activities.
2.4 | Statistical analysis
Data presented in this study are the means of three independent
experiments. Statistical differences were assessed using an unpaired
Student's t‐test with Bonferroni correction for multiple comparisons.
All data are presented as the mean ± standard deviation/error. For
values of p ≤ .05, differences were considered statistically significant.
3 | RESULTS
3.1 | Effects of AED on osteoclastogenesis
It was observed that valproic acid, at low doses (10−7M), promoted an
increase in the TRAP activity, being ~29% higher than the control (Figure
1a). At higher doses, it elicited a dose‐dependent decrease in cell
response. The other tested AED caused a dose‐dependent decrease in
that parameter, which became significant at 10−7M (~20% and ~25%
lower for gabapentin and lamotrigine, respectively) and 10−6M (~17%
and ~28% lower for carbamazepine and topiramate, respectively). A
similar pattern of response was observed when the amount of
osteoclastic cells (TRAP+multinucleated cells) in each experimental
condition was quantified (Figure 1b), that means, valproic acid was the
only AED that increased cell response (at 10−7M), whereas higher
concentration, and the other AED promoted a dose‐dependent decrease.
To analyze if the decrease in the amount of osteoclastic cells promoted
by the AED was due to an increase in cell death, the apoptotic response
was also evaluated (Figure 1c). It was observed that all the tested AED, at
low concentrations (10−8M) did not affect the caspase‐3 activity,
whereas at 10−6M only gabapentin and lamotrigine significantly
increased it (~31% and ~36%, respectively). At 10−4M, all the AED
caused a significant increase in apoptosis.
In all tested conditions it was possible to observe cells with
distinctive osteoclastic features namely, actin rings and expression of
VNR and CTR (Figure 2a). PBMC cultures treated with the minimum
concentration of each AED that caused a significant effect in the
TRAP activity were further characterized for additional parameters.
Regarding gene expression (Figure 2b), it was observed that valproic
acid was able to stimulate the expression of all analyzed genes,
namely, the osteoclastogenic factors c‐myc and c‐src and the
functional markers TRAP, CATK, and CA2 (~17–49% higher than
the control). On the other hand, all the other AED elicited a
significant decrease of gene expression (~16–47% lower than the
control). Calcium phosphate resorbing ability was also modulated by
the AED (Figure 2c). Once again, valproic acid was the only drug that
caused a significant increase in cell response (~71%), whereas the
other AED elicited a decrease in the resorbing ability (~26–50%).
Having established how the different AED affected osteoclast
differentiation and function, the involved intracellular mechanisms were
characterized (Figure 3). In the absence of any AED, PDTC completely
abolished the TRAP activity, whereas the remaining inhibitors caused a
partial inhibition in cell response. In the presence of valproic acid,
U0126 did not affect the TRAP activity, and SP600125 promoted a
sharp decrease on it. Carbamazepine treatment elicited a higher
inhibition in the presence of U0126 and GO6983, whereas SP600125
caused only a slight decrease in the TRAP activity. In the presence of
gabapentin U0126 did not affect cell response, and in the presence of
lamotrigine, it was GO6983 that did not change the TRAP activity.
Finally, following supplementation with topiramate, PBMC cultures
exhibited a lower response in the presence of U0126, and in the
presence of SP600125 TRAP activity was completely abolished.
TABLE 1 Primers used on qPCR analysis of PBMC and HMSC cultures
Gene 5′ Primer 3′ Primer
GUSB 5′‐TGCAGCGGTCTGTACTTCTG‐3′ 5′‐CCTTGACAGAGATCTGGTAATTCA‐3′
PSMB6 5′‐GCCGGCTACCTTACTACCTG‐3′ 5′‐AAACTGCACGGCCATGATA‐3′
c‐myc 5′‐TACCCTCTCAACGACAGCAG‐3′ 5′‐TCTTGACATTCTCCTCGGTG‐3′
c‐src 5′‐AAGCTGTTCGGAGGCTTCAA‐3′ 5′‐TTGGAGTAGTAGGCCACCAG‐3′
TRAP 5′‐ACCATGACCACCTTGGCAATGTCTC‐3′ 5′‐ATAGTGGAAGCGCAGATAGCCGTT‐3′
CATK 5′‐AGGTTCTGCTGCTACCTGTGGTGAG‐3′ 5′‐CTTGCATCAATGGCCACAGAGACAG‐3′
CA2 5′‐GGACCTGAGCACTGGCATAAGGACT‐3′ 5′‐AAGGAGGCCACGAGGATCGAAGTT‐3′
COL1 5′‐TCCGGCTCCTGCTCCTCTTA‐3′ 5′‐ACCAGCAGGACCAGCATCTC‐3′
ALP 5′‐ACGTGGCTAAGAATGTCATC‐3′ 5′‐CTGGTAGGCGATGTCCTTA‐3′
BMP‐2 5′‐GACGAGGTCCTGAGCGAGTT‐3′ 5′‐GCAATGGCCTTATCTGTGAC‐3′
Note. HMSC: human mesenchymal stem cells; PBMC: human peripheral blood mononuclear cells; q‐PCR: quantitative real‐time polymerase chain reaction.
3.2 | Effects of AED on osteoblastogenesis
At low doses, valproic acid and topiramate elicited a significant increase
in the ALP activity, being ~23% with 10−6M valproic acid, and ~14%
with 10−7M topiramate (Figure 4a). At higher concentrations, both AED
caused a decrease in cell response. The other AED promoted a dose‐
dependent inhibition of the ALP activity, which became significant at
10−7M (~12% for gabapentin) and at 10−6M (~12% and ~14% for
carbamazepine and lamotrigine, respectively). At 10−6M, valproic acid
F IGURE 1 Dose–response curves of PBMC cultures treated with different AED (valproic acid, carbamazepine, gabapentin, lamotrigine, and
topiramate). Tested concentrations: 10−8M–10−4 M. Cellular behavior was assessed at days 7, 14, and 21. Cell cultures performed in the
absence of any AED were used as negative control. (a) The TRAP activity, assessed by pNPP hydrolysis method. (b) TRAP +multinucleated cells
quantification by optic microscopy following staining). White bar represents 100 µm. (c) Caspase‐3‐activity assessed by fluorescence
quantification. *Significantly different from the control. AED: antiepileptic drugs; PBMC: human peripheral blood mononuclear cells; TRAP:
tartrate‐resistant acid phosphatase [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 2 Effects of AED (valproic acid, carbamazepine, gabapentin, lamotrigine, and topiramate) on PBMC cultures. (a) Representative
images of confocal microscopy showing the presence of cells with actin rings (blue) and expressing vitronectin and calcitonin receptors (VNR
and CTR, respectively) (green); white bars represent 220 µm. (b) Expression of osteoclast‐related genes, namely, the osteoclastogenic factors
c‐myc and c‐src and the osteoclastic functional genes TRAP, CATK, and CA2. (c) Calcium phosphate resorbing ability after 21 days of culture in
the presence of the tested AED. *Significantly different from the control. AED: antiepileptic drugs; PBMC: human peripheral blood mononuclear
cells [Color figure can be viewed at wileyonlinelibrary.com]
and topiramate promote an increase in calcium deposits, whereas the
remaining drugs elicited an opposite response (Figure 4b). Regarding
cell viability (Figure 4c), all the tested AED caused a dose‐dependent
decrease, which was significant at 10−6M (~16%, ~17% and ~14% for
valproic acid, carbamazepine, and topiramate, respectively) and 10−5M
(~10% and ~14% for gabapentin and lamotrigine, respectively). At
10−8M none of the tested AED affected apoptosis (Figure 4d), and at
10−6M only valproic acid and topiramate promoted a significant
increase (~44% and ~29%, respectively). All tested AED, at 10−4M,
prompted an increase in the caspase‐3 activity (~45–80%).
F IGURE 3 Modulation of MEK, NFkB, PKC, and JNK signaling pathways by AED, in PBMC cultures. The tested concentration of each AED
was selected according to the dose–response curves performed for each drug. Cell response was evaluated by the TRAP activity. *Significantly
different from the control. AED: antiepileptic drugs; PBMC: human peripheral blood mononuclear cells; TRAP: tartrate‐resistant acid
phosphatase
F IGURE 4 Dose–response curves of HMSC cultures treated with different AED (valproic acid, carbamazepine, gabapentin, lamotrigine, and
topiramate). Tested concentrations: 10−8M–10−4 M. Cellular behavior was assessed at days 7, 14, and 21. Cell cultures performed in the
absence of any AED were used as negative control. (a) The ALP activity, assessed by the pNPP hydrolysis method. (b) Representative images of
HMSC after Alizarin Red staining. Black bars represent 120 µm. (c) Cell viability, assessed by the MTT assay. (d) The Caspase‐3‐activity assessed
by fluorescence quantification. *Significantly different from the control. AED: antiepileptic drugs; HMSC: human mesenchymal stem cells; MTT:
3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide [Color figure can be viewed at wileyonlinelibrary.com]
In all tested conditions, cells were well‐spread and exhibited a
normal morphology, with distinctive cell‐to‐cell contacts between
them (Figure 5a). Regarding gene expression (Figure 5b), valproic
acid and topiramate elicited a significant increase on the expression
of the functional genes COL1, ALP, and BMP2 (~52–98%), whereas
the remaining three AED caused a decrease in the expression of the
analyzed genes (~27–49%).
After the characterization of the effects of the different AED on
osteoblast differentiation, the associated intracellular mechanisms
were analyzed (Figure 6). It was observed that, in negative control
condition (absence of any AED), all the used inhibitors promoted a
partial decrease in the ALP activity, although GO6983‐related
inhibition did not reach significance. In the presence of valproic acid,
U0126 and GO6983 caused a lower decrease in cell response; on the
other hand SP600125 caused a sharper decrease than in the negative
control. Cultures performed in the presence of carbamazepine were
not significantly affected by U0126, whereas GO6983 displayed an
increase in its inhibitory effect. Supplementation with gabapentin
promoted a lower decrease of the ALP activity in the presence of
SP600125, and an absence of inhibition in the presence of PDTC;
GO6983 caused a higher inhibition, compared with the negative
control. Cell cultures performed with topiramate were not signifi-
cantly affected by U0126 and SP600125.
4 | DISCUSSION
AED are a class of drugs used worldwide, not only for the treatment
of epilepsy, but also in cases of convulsions, seizures, pain,
neuropathy, and psychiatric disorders (Fan et al., 2016; Hant &
Bolster, 2016; Pitetzis et al., 2017). They present many potential
side effects, including dizziness, drowsiness, mental slowing, skin
rashes, hepatotoxicity, pancreatic insufficiency, behavioral disorders,
increased risk of metabolic syndrome, and nephrolithiasis (Fan et al.,
2016; Lin et al., 2016). Also, disruption of bone metabolism is
described for decades, although the exact consequences in bone
F IGURE 5 Effects of AED (valproic acid, carbamazepine, gabapentin, lamotrigine, and topiramate) on PBMC cultures. (a) Representative
images of confocal microscopy showing the presence of cells stained for actin (blue); white bars represent 60 µm. (b) Expression of osteoblast‐
related genes, namely, the functional genes COL1, ALP, and BMP2. *Significantly different from the control. AED: antiepileptic drugs; PBMC:
human peripheral blood mononuclear cells [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 6 Modulation of MEK, NFkB, PKC, and JNK signaling pathways by AED, in HMSC cultures. The tested concentration of each AED
was selected according to the dose–response curves performed for each drug. Cell response was evaluated by the ALP activity. *Significantly
different from the control. AED: antiepileptic drugs; ALP: alkaline phosphatase; HMSC: human mesenchymal stem cells
tissue remain elusive. In this study, the effects of five different AED
on human primary bone cells (osteoclasts and osteoblasts) were
characterized.
The tested AED were the valproic acid, carbamazepine, gaba-
pentin, lamotrigine, and topiramate. The first two are classical AED,
which are members of the first generation of this class, whereas
gabapentin, lamotrigine, and topiramate belong to the newer class of
AED, being apparently safer and better tolerated by patients (Fan
et al., 2016). The AED were selected expecting to include molecules
with different mechanisms of action, and the tested concentrations
were chosen to include the plasma concentration achieved following
a common therapeutic usage of each drug (Abou‐Khalil, 2005;
Haroutiunian et al., 2009; O'Dougherty et al., 1987; Popov et al.,
2013; Rose & Kam, 2002). However, it is important to highlight that
those values may not represent the exact concentrations present in
bone tissue, because the vascularization and the particular char-
acteristics of its extracellular matrix contribute to a specific
biochemical microenvironment in that tissue.
Valproic acid is short‐chain fatty acid with a branched structure,
derived from valeric acid. It displays antiepileptic properties, being
also prescribed in other pathological conditions, such as migraine and
bipolar disease (Pitetzis et al., 2017). It has some important cellular
effects, namely, inhibition of cytochrome P450, promotion of histone
acetylation, and modulation of several cellular functions, differentia-
tion, and apoptosis (Pitetzis et al., 2017). Regarding its side effects,
valproic acid is by far the better studied AED, being associated to
hepatotoxicity, pancreatitis, teratogenicity, and an increased risk to
develop metabolic syndrome. In addition, there are many reports
claiming that valproic acid is linked to a significant decrease in bone
mineral density and to an increase in bone fracture risk (Albaghdadi,
Alhalabi, Alourfi, & Youssef, 2016; Ecevit et al., 2004; Gniatkowska‐
Nowakowska, 2010; Guo et al., 2001; Hamed, Moussa, Youssef, Abd
ElHameed, & NasrEldin, 2014; Lee, Lyles, & Colon‐Emeric, 2010;
Tsukahara et al., 2002; Zhang, Zheng, Zhu, Zhang, & Zheng, 2015). It
has also been suggested that valproic acid delays growth velocity
(Lee et al., 2013; Lin et al., 2016). Nevertheless, other studies failed
to prove any relationship between valproic acid consumption and
disturbances in bone metabolism (Elliott, Jacobson, & Haneef, 2007;
Kim, Lee, Choi, Chung, & Lee, 2007; Serin, Koc, Temelli, & Esen, 2015;
Shen et al., 2014; Triantafyllou et al., 2010). Regarding bone turnover
markers, there are also conflicting data, stating that valproic acid
increases (Kim et al., 2007; Oner et al., 2004; Verrotti, Agostinelli,
Coppola, Parisi, & Chiarelli, 2010), decreases (Song et al., 2005;
Tsukahara et al., 2002) or does not affect osteocalcin serum levels. In
more detail, ALP levels seem to be increased by this drug (Lin et al.,
2016; Verrotti et al., 2010), as well as bone resorption markers, such
as ionized plasma calcium, carboxyterminal telopeptide of type I
collagen (Sato et al., 2001), and the plasma TRAP activity (Lin et al.,
2016; Rauchenzauner et al., 2010). On the other hand, in a study with
female children and adolescents, valproic acid appeared to promote a
decrease in serum TRAP levels (Lin et al., 2016).
Carbamazepine is an iminodibenzyl derivative that belongs to the
conventional enzyme‐inducing antiepileptic drugs (AED), which displays
the ability to induce hepatic cytochrome P450 function (Pitetzis et al.,
2017). It is widely used for the treatment of partial and secondary
generalized seizures (Mantegazza, Curia, Biagini, Ragsdale, & Avoli,
2010). Besides nausea, vomiting, weight gain, and other common side
effects, carbamazepine has been also associated with bone loss and
increased risk of fracture (Jette et al., 2011), though there are also
reports that state an increase in bone formation markers (Verrotti,
Greco, Latini, Morgese, & Chiarelli, 2002).
Gabapentin presents a chemical structure with similarities with
GABA (Fan et al., 2016). It has a high lipophilicity, being effective in
the treatment of headaches, inflammatory pain, and several neuro-
pathy‐associated pains (Rose & Kam, 2002). It presents as the most
relevant side effects, sexual dysfunction, weight gain, dizziness,
fatigue, and bone loss and increased risk of fracture (Andress et al.,
2002; Jette et al., 2011).
Lamotrigine is a newer non‐enzyme‐inducer AED that is effective
in the treatment of clonic‐tonic and partial seizures (Fan et al., 2016).
Its main side effects include headache, dizziness, sedation, insomnia,
and ataxia. Furthermore, it has been linked to bone loss, disturbed
child growth and decreased bone mineral density (Andress et al.,
2002; Guo et al., 2001), although this effect seems so be particularly
relevant when lamotrigine is administered in combination with
valproic acid (Guo et al., 2001). However, there are also studies that
have failed to demonstrate a strong relationship between lamotrigine
and bone metabolic imbalances (Kim et al., 2007).
Topiramate is a derivative of fructose (Fan et al., 2016). It is a
non‐enzyme‐inducer AED approved as an adjuvant for primary
clonic‐tonic and partial seizures, as well as a prophylactic agent in
migraines, depression, bipolar disorder, and among others (Lyseng‐
Williamson & Yang, 2007). Its most common adverse effects are
somnolence, paresthesia, poor concentration, and weight loss (Fan
et al., 2016; Lyseng‐Williamson & Yang, 2007). In addition,
topiramate has also been linked to disturbances in bone metabolism,
namely, abnormal BMD (Ali, Herial, Orris, Horrigan, & Tietjen, 2011;
Coppola et al., 2009). One possible explanation for these effects is
the fact that this molecule inhibits carbonic anhydrase, which can
promote metabolic acidosis and, consequently, can lead to a decrease
in mineral content of bone. However, one cannot exclude other
mechanisms of action neither a potential direct effect of the drug in
bone cells, though there are no reports about this issue.
Globally, the effects of AED in bone metabolism still controver-
sial, but growing evidence points to imbalances in bone turnover and
an increased risk of fracture (Kim et al., 2007; Pitetzis et al., 2017;
Tsukahara et al., 2002). On one hand, the risk of fracture seems to be
higher in the case of P450‐modulator drugs, such as valproic acid or
carbamazepine (Hant & Bolster, 2016). Despite the consequences on
bone tissue, the AED modulation of bone metabolism may occur by
different ways. They may exert their effects on bone tissue via
indirect mechanisms, such as stimulation of vitamin D catabolism
and, consequently, a decrease on intestinal calcium absorption and
parathyroid hormone secretion (Pitetzis et al., 2017). However, it is
also possible that at least some of them may have direct actions on
the differentiation and function of bone cells, particularly at
osteoclast and osteoblast level, an issue that is extremely poor
documented.
In the present work, it was observed that all the tested AED had
the ability to affect human osteoclastogenesis. Among the five AED,
only valproic acid was able to stimulate the process, at low doses.
These effects were related not only to the differentiation process,
but also to the resorbing function of mature osteoclasts. At least
partially, some of the results may be related to an increase in
apoptosis, because at high doses all the tested AED stimulated the
process. The different AED also caused differential effects on the
expression of different genes involved in the osteoclast development
and function (c‐myc, c‐src, TRAP, CATK, and CA2), that were
dependent of the dose of each AED. Globally the pattern of response
was similar to that observed in the TRAP activity. Although in some
experimental conditions the magnitude of the response was some-
how low, it is important to note that any increase in gene
transcription may be associated with significant changes in the
production of the corresponding protein, because each mRNA can be
translated multiple times. The AED also affected the resorbing
function of osteoclasts. Once again, valproic acid was able to elicit an
increase in cell response, whereas the remaining AED promoted an
inhibition of cell response. Regarding the involved intracellular
mechanisms, the results pointed to differential effects caused by
the different drugs, which is not surprising, because although they
belong to the same pharmacological family, they are chemically very
different and, thus, present different mechanisms of action. The MEK
pathway appeared to be more relevant in the presence of
carbamazepine and topiramate, but not important in the presence
of gabapentin. Valproic acid and lamotrigine elicited a downregula-
tion of PKC, whereas carbamazepine downregulated it. JNK was
critical for osteoclastogenesis following supplementation with topir-
amate, whereas an opposite situation was observed with carbama-
zepine. To have a more detailed perspective about the specific
mechanisms affected by each AED, the analysis of the expression
and, in some cases, phosphorylation/dephosphorylation ratio of
different intracellular molecules involved in important signaling
pathways, should be conducted. This study is underway.
Osteoblastogenesis was stimulated by low doses of valproic acid
and topiramate, whereas the remaining AED promoted a dose‐
dependent decrease of the process. A similar behavior was observed
regarding the presence of calcium deposits, assessed by alizarin red
staining. The observed stimulatory effects were not due to an
increase in cell viability, which suggests specific effects in the
differentiation process. In line with this, apoptosis seemed to be
stimulated at high doses of the AED. Regarding gene expression,
valproic acid and topiramate promoted an increase in the expression
of the functional genes COL1, ALP, and BMP2, whereas the remaining
AED elicit an opposite response. The intracellular mechanisms
modulated by the different AED were diverse. The MEK pathway
seemed to be particularly important in the presence of valproic acid
and gabapentin, and not involved in osteogenesis in the presence of
carbamazepine and topiramate. Valproic acid, carbamazepine, and
gabapentin elicited an upregulation of PKC, whereas all tested AED,
except carbamazepine promoted a downregulation of the JNK
pathway. As stated above, the analysis of specific changes in
intracellular proteins involved in the tested pathways is underway.
A couple of previously published studies aimed to investigate the
effects of valproic acid on bone cells, both with osteoblastic cell lines.
It was observed that it stimulated cell proliferation and differentia-
tion of mouse MC3T3‐E1 osteoblastic cell line (Schroeder &
Westendorf, 2005). On the other hand, on human osteoblastic cell
line hFOB 1.19, valproic acid seemed to cause a decrease in collagen
type 1 and osteonectin production, but did not affect RANKL
production (Humphrey et al., 2013). These observations suggest that
valproic acid may be an important modulator of osteogenesis. In
addition, valproic acid promoted a decrease in the proliferation of a
mouse mesenchymal stem cell line (C3H10T1/2), at concentrations
higher than 10−4M (Hatakeyama et al., 2011). At present, there are
no reports aiming to characterize the effects of other AED, in
addition to valproic acid, on osteoblastic cells, neither studies
conducted with AED and osteoclastic cells.
In conclusion, it was demonstrated that the different AED can
directly modulate human osteoclastogenesis and osteoblastogenesis,
which may account, at least partially, to some of the potential
deleterious effects of AED in bone metabolism. Among the tested
AED, valproic acid appeared to have the ability to interfere positively
with both processes, which suggests a possible increase in bone
turnover rate. The remaining AED displayed an inhibition of both
processes (carbamazepine, gabapentin, and lamotrigine) or an
inhibition of osteoclastogenesis and a stimulation of osteoblastogen-
esis (topiramate). This is the first report describing the direct effects
of different AED on human primary bone cells, which is a very
important issue, because these drugs are usually consumed in long‐
term therapeutics, with acknowledged in vivo effects in bone tissue.
Understanding how AED affect bone tissue metabolism and integrity
may help to develop new drugs and adjust therapeutics to each
patient individual characteristics aiming to better clinical outcomes
with minimal bone tissue‐associated consequences.
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